{"id":9454,"date":"2025-09-02T06:25:37","date_gmt":"2025-09-02T11:25:37","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9454"},"modified":"2025-10-13T06:34:02","modified_gmt":"2025-10-13T11:34:02","slug":"nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ar\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/","title":{"rendered":"\u062a\u0639\u0632\u0632 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u0627\u0644\u0645\u0633\u0627\u0631\u0627\u062a \u0627\u0644\u062a\u0646\u0638\u064a\u0645\u064a\u0629 \u0627\u0644\u0639\u0627\u0644\u0645\u064a\u0629 \u0644\u0639\u0642\u0627\u0631 MCO-010 \u0645\u0646 \u062e\u0644\u0627\u0644 \u062d\u0635\u0648\u0644\u0647 \u0639\u0644\u0649 \u0645\u0648\u0627\u0641\u0642\u0629 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA RMAT) \u0648\u062e\u0645\u0633\u0629 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0644\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u064a\u062a\u064a\u0645\u0629 \u0645\u0646 \u0648\u0643\u0627\u0644\u0629 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 (EMA)."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
<\/div><\/div><\/div><\/header>

\u062a\u0645\u0646\u062d \u0648\u0643\u0627\u0644\u0629 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 MCO-010 \u062e\u0645\u0633\u0629 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0644\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u064a\u062a\u064a\u0645\u0629 \u0639\u0628\u0631 \u0645\u062c\u0645\u0648\u0639\u0629 \u0648\u0627\u0633\u0639\u0629 \u0645\u0646 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u062a\u064a \u062a\u0634\u0645\u0644 \u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0629 \u0644\u0644\u0636\u0648\u0621\u060c \u0628\u0645\u0627 \u0641\u064a \u0630\u0644\u0643 \u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0645\u062a\u0644\u0627\u0632\u0645\u064a\u0629 \u0648\u063a\u064a\u0631 \u0627\u0644\u0645\u062a\u0644\u0627\u0632\u0645\u064a\u0629\u060c \u0648\u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u062a\u064a \u064a\u0647\u064a\u0645\u0646 \u0639\u0644\u064a\u0647\u0627 \u0627\u0644\u0639\u0635\u064a \u0648\u0627\u0644\u0645\u062e\u0627\u0631\u064a\u0637\u060c \u0648\u0636\u0645\u0648\u0631 \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621.<\/i><\/h3>

\u0645\u0646\u062d\u062a \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA) \u062f\u0648\u0627\u0621 MCO-010 \u062a\u0635\u0646\u064a\u0641 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0645\u062a\u0642\u062f\u0645 \u0644\u0644\u0637\u0628 \u0627\u0644\u062a\u062c\u062f\u064a\u062f\u064a (RMAT)\u060c \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u064a\u062a\u064a\u0645\u0629 \u0648\u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064a\u0639 \u0627\u0644\u062d\u0627\u0644\u064a\u0629\u060c \u0644\u0639\u0644\u0627\u062c \u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a.<\/i><\/h3>

\u062a\u0639\u0645\u0644 \u0634\u0631\u0643\u0629 Nanoscope \u0639\u0644\u0649 \u0625\u0639\u0627\u062f\u0629 \u062a\u0639\u0631\u064a\u0641 \u0645\u0639\u0627\u064a\u064a\u0631 \u0627\u0644\u0631\u0639\u0627\u064a\u0629 \u0644\u062d\u0627\u0644\u0627\u062a \u0627\u0644\u062a\u0646\u0643\u0633 \u0627\u0644\u0634\u0628\u0643\u064a \u0630\u0627\u062a \u0627\u0644\u0627\u062d\u062a\u064a\u0627\u062c\u0627\u062a \u0627\u0644\u0639\u0627\u0644\u064a\u0629 \u063a\u064a\u0631 \u0627\u0644\u0645\u0644\u0628\u0627\u0629 \u0645\u0646 \u062e\u0644\u0627\u0644 \u0645\u0646\u0635\u062a\u0647\u0627 \u0627\u0644\u0628\u0635\u0631\u064a\u0629 \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629 MCO-010 \u063a\u064a\u0631 \u0627\u0644\u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0645\u0631\u0636 \u0645\u0639\u064a\u0646.<\/i><\/h3><\/div><\/div><\/section>

\u062f\u0627\u0644\u0627\u0633<\/span><\/span>,\u00a02 \u0633\u0628\u062a\u0645\u0628\u0631 2025<\/span><\/span>\u00a0\u2014\u00a0\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u0644\u0644\u0639\u0644\u0627\u062c\u0627\u062a<\/a>, \u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0627\u0644\u062a\u0643\u0646\u0648\u0644\u0648\u062c\u064a\u0627 \u0627\u0644\u062d\u064a\u0648\u064a\u0629\u060c \u0627\u0644\u0645\u0644\u062a\u0632\u0645\u0629 \u0628\u062a\u0637\u0648\u064a\u0631 \u0648\u062a\u0633\u0648\u064a\u0642 \u0639\u0644\u0627\u062c\u0627\u062a \u0645\u0628\u062a\u0643\u0631\u0629 \u0644\u0627 \u062a\u0631\u062a\u0628\u0637 \u0628\u0645\u0631\u0636 \u0645\u062d\u062f\u062f\u060c \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0629 \u0644\u0644\u0636\u0648\u0621 \u0648\u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u0646\u0627\u062a\u062c \u0639\u0646 \u062a\u0646\u0643\u0633 \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0627\u0644\u064a\u0648\u0645 \u0623\u0646 \u0648\u0643\u0627\u0644\u0629 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 (EMA) \u0645\u0646\u062d\u062a \u062f\u0648\u0627\u0621 MCO-010 (sonpiretigene isteparvovec) \u062a\u0635\u0646\u064a\u0641 \u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0644\u062e\u0645\u0633 \u0641\u0626\u0627\u062a \u0645\u0646 \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629. \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u0630\u0644\u0643\u060c \u0645\u0646\u062d\u062a \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA) \u062f\u0648\u0627\u0621 MCO-010 \u062a\u0635\u0646\u064a\u0641 RMAT \u0644\u0639\u0644\u0627\u062c \u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a (SD).<\/p>

The EMA Orphan designations cover non-syndromic and syndromic rod-dominant and cone-dominant dystrophies, as well as macular dystrophies, providing a potential disease-agnostic regulatory path forward for dozens of retinal conditions. The new FDA RMAT designation for SD builds on prior Orphan Drug and Fast Track designations for both retinitis pigmentosa (RP) and SD. The EMA and FDA actions underscore regulatory agency recognition of MCO-010’s potential to address significant unmet needs in retinal degenerative diseases.<\/p>

“Securing RMAT designation for Stargardt disease in addition to our prior FDA designations for SD and RP is a major validation for our therapies that warrant expedited development and review,” said\u00a0\u0633\u0648\u0644\u0627\u062c\u0646\u0627 \u0628\u0647\u0627\u062a\u0627\u0634\u0627\u0631\u064a\u0627<\/span>, CEO of Nanoscope. “Combined with five EMA Orphan designations, these achievements highlight the global momentum behind our MCO platform as a potential vision-restoring therapy for patients with few or no treatment options.”<\/p>

MCO (\u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f \u0627\u0644\u062e\u0635\u0627\u0626\u0635) \u0647\u0648 \u0639\u0644\u0627\u062c \u064a\u064f\u0639\u0637\u0649 \u0644\u0645\u0631\u0629 \u0648\u0627\u062d\u062f\u0629 \u0641\u064a \u0627\u0644\u0639\u064a\u0627\u062f\u0629\u060c \u0648\u064a\u064f\u062d\u0642\u0646 \u062f\u0627\u062e\u0644 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a \u0644\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0648\u0647\u0648 \u063a\u064a\u0631 \u0645\u0631\u062a\u0628\u0637 \u0628\u0645\u0631\u0636 \u0645\u0639\u064a\u0646\u060c \u0648\u0645\u0635\u0645\u0645 \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u062a\u0646\u0643\u0633 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0629 \u0644\u0644\u0636\u0648\u0621\u060c \u0628\u0645\u0627 \u0641\u064a \u0630\u0644\u0643 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a\u060c \u0648\u0645\u0631\u0636 \u0627\u0635\u0641\u0631\u0627\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0648\u0627\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a. \u064a\u0639\u0645\u0644 MCO \u0639\u0646 \u0637\u0631\u064a\u0642 \u062a\u0646\u0634\u064a\u0637 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u062b\u0646\u0627\u0626\u064a\u0629 \u0627\u0644\u0642\u0637\u0628 \u0639\u0627\u0644\u064a\u0629 \u0627\u0644\u0643\u062b\u0627\u0641\u0629 \u0641\u064a \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0644\u062a\u0635\u0628\u062d \u062d\u0633\u0627\u0633\u0629 \u0644\u0644\u0636\u0648\u0621\u060c \u0645\u0633\u062a\u0641\u064a\u062f\u064b\u0627 \u0645\u0646 \u0627\u0644\u062f\u0648\u0627\u0626\u0631 \u0627\u0644\u0628\u0635\u0631\u064a\u0629 \u0627\u0644\u0645\u062a\u0628\u0642\u064a\u0629 \u0628\u0639\u062f \u0645\u0648\u062a \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0629 \u0644\u0644\u0636\u0648\u0621. \u0644\u0627 \u064a\u062a\u0637\u0644\u0628 MCO \u0627\u062e\u062a\u0628\u0627\u0631\u0627\u062a \u062c\u064a\u0646\u064a\u0629\u060c \u0623\u0648 \u062a\u062f\u062e\u0644\u0627\u064b \u062c\u0631\u0627\u062d\u064a\u064b\u0627\u060c \u0623\u0648 \u062c\u0631\u0639\u0627\u062a \u0645\u062a\u0643\u0631\u0631\u0629\u060c \u0645\u0645\u0627 \u064a\u062a\u064a\u062d \u062a\u0637\u0628\u064a\u0642\u0647 \u0639\u0644\u0649 \u0646\u0637\u0627\u0642 \u0648\u0627\u0633\u0639 \u0645\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0636\u0645\u0646 \u0625\u062c\u0631\u0627\u0621\u0627\u062a \u0627\u0644\u0639\u0645\u0644 \u0627\u0644\u062d\u0627\u0644\u064a\u0629 \u0641\u064a \u0639\u064a\u0627\u062f\u0627\u062a \u0627\u0644\u0634\u0628\u0643\u064a\u0629.<\/p>

Nanoscope’s vision-improving clinical programs are advancing globally, with positive Phase\u00a02\u0628<\/span>\u0623\u0638\u0647\u0631\u062a \u0646\u062a\u0627\u0626\u062c \u062a\u062c\u0631\u0628\u0629 RESTORE \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0646\u062a\u0627\u0626\u062c \u0645\u0634\u062c\u0639\u0629 \u0641\u064a \u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a\u060c \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u0646\u062a\u0627\u0626\u062c \u0645\u0634\u062c\u0639\u0629 \u0645\u0646 \u062a\u062c\u0631\u0628\u0629 STARLIGHT \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0641\u064a \u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u062c\u0644\u062f \u0627\u0644\u062a\u0623\u062a\u0628\u064a. \u0648\u0645\u0646 \u0627\u0644\u0645\u062a\u0648\u0642\u0639 \u0623\u0646 \u062a\u0628\u062f\u0623 \u062a\u062c\u0631\u0628\u0629 \u062a\u0633\u062c\u064a\u0644\u064a\u0629 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0641\u064a \u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u062c\u0644\u062f \u0627\u0644\u062a\u0623\u062a\u0628\u064a\u060c \u0648\u062a\u062c\u0631\u0628\u0629 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0641\u064a \u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u062c\u0644\u062f \u0627\u0644\u062a\u0623\u062a\u0628\u064a\u060c \u0628\u062d\u0644\u0648\u0644 \u0646\u0647\u0627\u064a\u0629 \u0639\u0627\u0645 2025.<\/p>

\u062a\u0624\u062b\u0631 \u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633 \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0628\u0645\u0627 \u0641\u064a \u0630\u0644\u0643 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a\u060c \u0648\u0645\u0631\u0636 \u062a\u0635\u0644\u0628 \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621\u060c \u0648\u0636\u0645\u0648\u0631 \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621\u060c \u0648\u0627\u0636\u0637\u0631\u0627\u0628\u0627\u062a \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0645\u062a\u0644\u0627\u0632\u0645\u064a\u0629\u060c \u0639\u0644\u0649 \u0645\u0644\u0627\u064a\u064a\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u062d\u0648\u0644 \u0627\u0644\u0639\u0627\u0644\u0645. \u0647\u0630\u0647 \u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u062a\u063a\u064a\u0631 \u0645\u062c\u0631\u0649 \u062d\u064a\u0627\u0629 \u0627\u0644\u0645\u0631\u0636\u0649\u060c \u0648\u062a\u0633\u0628\u0628 \u0644\u0647\u0645 \u0625\u0639\u0627\u0642\u0629 \u0645\u0632\u0645\u0646\u0629\u060c \u0648\u062a\u0641\u062a\u0642\u0631 \u0625\u0644\u0649 \u062e\u064a\u0627\u0631\u0627\u062a \u0639\u0644\u0627\u062c\u064a\u0629 \u0641\u0639\u0627\u0644\u0629 \u0639\u0644\u0649 \u0646\u0637\u0627\u0642 \u0648\u0627\u0633\u0639. \u0641\u064a \u0627\u0644\u0627\u062a\u062d\u0627\u062f \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u060c \u064a\u062a\u064a\u062d \u0648\u0636\u0639 "\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645" \u0644\u062f\u0649 \u0648\u0643\u0627\u0644\u0629 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 \u0641\u0631\u0635\u064b\u0627 \u0644\u0644\u062d\u0635\u0648\u0644 \u0639\u0644\u0649 \u0627\u0644\u0645\u0633\u0627\u0639\u062f\u0629 \u0641\u064a \u0648\u0636\u0639 \u0627\u0644\u0628\u0631\u0648\u062a\u0648\u0643\u0648\u0644\u0627\u062a \u0627\u0644\u0639\u0644\u0627\u062c\u064a\u0629\u060c \u0648\u0645\u0627 \u064a\u0635\u0644 \u0625\u0644\u0649 10 \u0633\u0646\u0648\u0627\u062a \u0645\u0646 \u0627\u0644\u062d\u0635\u0631\u064a\u0629 \u0627\u0644\u062a\u0633\u0648\u064a\u0642\u064a\u0629 \u0628\u0639\u062f \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629.\u00a0\u0627\u0644\u0648\u0644\u0627\u064a\u0627\u062a \u0627\u0644\u0645\u062a\u062d\u062f\u0629<\/span>, \u062a\u0648\u0641\u0631 \u062a\u0635\u0646\u064a\u0641\u0627\u062a Orphan \u0648 Fast Track \u0648 RMAT \u0641\u0631\u0635\u064b\u0627 \u0644\u0644\u062a\u0637\u0648\u064a\u0631 \u0648\u0627\u0644\u0645\u0631\u0627\u062c\u0639\u0629 \u0627\u0644\u0645\u062a\u0633\u0627\u0631\u0639\u0629\u060c \u0648\u0627\u0644\u0645\u0631\u0648\u0646\u0629 \u0641\u064a \u062a\u0635\u0645\u064a\u0645 \u0627\u0644\u062a\u062c\u0627\u0631\u0628\u060c \u0648\u0633\u0628\u0639 \u0633\u0646\u0648\u0627\u062a \u0645\u0646 \u0627\u0644\u062d\u0635\u0631\u064a\u0629 \u0627\u0644\u0633\u0648\u0642\u064a\u0629 \u0639\u0646\u062f \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629.<\/p>

\u0646\u0628\u0630\u0629 \u0639\u0646 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633<\/b><\/p>

\u062a\u0639\u0645\u0644 \u0634\u0631\u0643\u0629 Nanoscope Therapeutics \u0639\u0644\u0649 \u062a\u0637\u0648\u064a\u0631 \u0639\u0644\u0627\u062c \u0628\u0635\u0631\u064a \u0648\u0631\u0627\u062b\u064a \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631\u060c \u0628\u063a\u0636 \u0627\u0644\u0646\u0638\u0631 \u0639\u0646 \u0646\u0648\u0639 \u0627\u0644\u0645\u0631\u0636\u060c \u0644\u0645\u0644\u0627\u064a\u064a\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u0641\u0642\u062f\u0648\u0627 \u0628\u0635\u0631\u0647\u0645 \u0628\u0633\u0628\u0628 \u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633\u064a\u0629 \u0641\u064a \u0627\u0644\u0634\u0628\u0643\u064a\u0629. \u0648\u0630\u0644\u0643 \u0628\u0639\u062f \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0625\u064a\u062c\u0627\u0628\u064a\u0629 \u0627\u0644\u062a\u064a \u062d\u0642\u0642\u062a\u0647\u0627 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062a\u062c\u0631\u064a\u0628\u064a\u0629 RESTORE.\u00a02\u0628<\/span>\/3 \u062a\u062c\u0631\u0628\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0645\u0631\u0627\u0643\u0632\u060c \u0639\u0634\u0648\u0627\u0626\u064a\u0629\u060c \u0645\u0632\u062f\u0648\u062c\u0629 \u0627\u0644\u062a\u0639\u0645\u064a\u0629\u060c \u062e\u0627\u0636\u0639\u0629 \u0644\u0644\u062a\u062d\u0643\u0645 \u0627\u0644\u0648\u0647\u0645\u064a \u0644\u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP) (NCT04945772<\/a>\u0628\u062f\u0623\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u0625\u062c\u0631\u0627\u0621\u0627\u062a \u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0628\u064a\u0648\u0644\u0648\u062c\u064a (BLA) \u0625\u0644\u0649 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA). \u0641\u064a \u062d\u0627\u0644 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629\u060c \u064a\u064f\u062d\u062a\u0645\u0644 \u0623\u0646 \u064a\u0635\u0628\u062d MCO-010 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0642\u064a\u0627\u0633\u064a \u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP)\u060c \u062d\u064a\u062b \u064a\u064f\u0639\u0637\u0649 \u0643\u062d\u0642\u0646\u0629 \u0648\u0627\u062d\u062f\u0629 \u0641\u064a \u0627\u0644\u0639\u064a\u0627\u062f\u0629 \u062f\u0648\u0646 \u0627\u0644\u062d\u0627\u062c\u0629 \u0625\u0644\u0649 \u0627\u062e\u062a\u0628\u0627\u0631\u0627\u062a \u062c\u064a\u0646\u064a\u0629. \u0643\u0645\u0627 \u0623\u0638\u0647\u0631\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u0646\u062a\u0627\u0626\u062c \u0648\u0627\u0639\u062f\u0629 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 STARLIGHT \u0644\u0640 MCO-010 \u0641\u064a \u0639\u0644\u0627\u062c \u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a (SD).NCT05417126<\/a>) \u0648\u062a\u062e\u0637\u0637 \u0644\u0628\u062f\u0621\u00a0\u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u062a\u0633\u062c\u064a\u0644\u064a\u0629<\/a>\u00a0\u0641\u064a \u0639\u0627\u0645 2025\u060c \u062d\u0635\u0644 \u062f\u0648\u0627\u0621 MCO-010 \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064a\u0639 \u0648\u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0639\u0644\u0627\u062c \u0643\u0644 \u0645\u0646 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP) \u0648\u0645\u0631\u0636 \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 (SD)\u060c \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u062a\u0635\u0646\u064a\u0641 RMAT \u0644\u0645\u0631\u0636 \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0648\u062a\u0635\u0646\u064a\u0641\u0627\u062a \u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0645\u0646 \u0648\u0643\u0627\u0644\u0629 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 (EMA) \u0644\u062a\u063a\u0637\u064a\u0629 \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u063a\u064a\u0631 \u0627\u0644\u0645\u062a\u0644\u0627\u0632\u0645\u064a \u0648\u0627\u0644\u0645\u062a\u0644\u0627\u0632\u0645\u064a \u0627\u0644\u0630\u064a \u064a\u0647\u064a\u0645\u0646 \u0641\u064a\u0647 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0639\u0635\u0648\u064a\u0629 \u0648\u0627\u0644\u0645\u062e\u0631\u0648\u0637\u064a\u0629\u060c \u0641\u0636\u0644\u0627\u064b \u0639\u0646 \u0636\u0645\u0648\u0631 \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621. \u0648\u0645\u0646 \u0627\u0644\u0645\u062a\u0648\u0642\u0639 \u0623\u0646 \u064a\u0628\u062f\u0623 \u0628\u0631\u0646\u0627\u0645\u062c \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0644\u062f\u0648\u0627\u0621 MCO \u0641\u064a \u0639\u0644\u0627\u062c \u0627\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a (GA) \u0628\u062d\u0644\u0648\u0644 \u0646\u0647\u0627\u064a\u0629 \u0639\u0627\u0645 2025. \u0648\u062a\u0634\u0645\u0644 \u0627\u0644\u0628\u0631\u0627\u0645\u062c \u0627\u0644\u0623\u062e\u0631\u0649 \u0627\u0644\u062c\u0627\u0647\u0632\u0629 \u0644\u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628\u0627\u062a \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u062c\u062f\u064a\u062f\u0629 (IND) \u0639\u0644\u0627\u062c \u0627\u0644\u0639\u0645\u0649 \u0627\u0644\u062e\u0644\u0642\u064a \u0644\u0644\u064a\u0628\u0631 (LCA).<\/p>

\u0627\u062a\u0635\u0627\u0644:
<\/b>\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628
(817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>

\u0627\u0644\u0645\u0635\u062f\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

European Medicines Agency grants MCO-010 five Orphan designations across a wide spectrum of retinal diseases involving photoreceptor loss, including syndromic and non-syndromic, rod- and cone-dominant, and macular dystrophies. FDA grants MCO-010 Regenerative Medicine Advanced Therapy (RMAT) designation, in addition to current Orphan Drug and Fast Track designations, for Stargardt disease. Nanoscope is redefining the standard […]<\/p>\n","protected":false},"author":6,"featured_media":8971,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9454","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ar\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ar\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-02T11:25:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T11:34:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 \u062f\u0642\u0627\u0626\u0642\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/09\\\/02\\\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/09\\\/02\\\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations\",\"datePublished\":\"2025-09-02T11:25:37+00:00\",\"dateModified\":\"2025-10-13T11:34:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/09\\\/02\\\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\\\/\"},\"wordCount\":665,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/09\\\/02\\\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ar\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/09\\\/02\\\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/09\\\/02\\\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\\\/\",\"name\":\"Nanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/09\\\/02\\\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/09\\\/02\\\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"datePublished\":\"2025-09-02T11:25:37+00:00\",\"dateModified\":\"2025-10-13T11:34:02+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/09\\\/02\\\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/09\\\/02\\\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/09\\\/02\\\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"width\":1200,\"height\":242},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/09\\\/02\\\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0639\u0632\u0632 \u0645\u0633\u0627\u0631\u0627\u062a\u0647\u0627 \u0627\u0644\u062a\u0646\u0638\u064a\u0645\u064a\u0629 \u0627\u0644\u0639\u0627\u0644\u0645\u064a\u0629 \u0644\u0639\u0642\u0627\u0631 MCO-010 \u0628\u062d\u0635\u0648\u0644\u0647\u0627 \u0639\u0644\u0649 \u0645\u0648\u0627\u0641\u0642\u0629 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA) \u0648\u062e\u0645\u0633\u0629 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0644\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u064a\u062a\u064a\u0645\u0629 \u0645\u0646 \u0648\u0643\u0627\u0644\u0629 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 (EMA) - \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ar\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/","og_locale":"ar_AR","og_type":"article","og_title":"Nanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ar\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-09-02T11:25:37+00:00","article_modified_time":"2025-10-13T11:34:02+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"Nanoscope Therapeutics","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"3 \u062f\u0642\u0627\u0626\u0642"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations","datePublished":"2025-09-02T11:25:37+00:00","dateModified":"2025-10-13T11:34:02+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/"},"wordCount":665,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ar"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/","url":"https:\/\/nanostherapeutics.com\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0639\u0632\u0632 \u0645\u0633\u0627\u0631\u0627\u062a\u0647\u0627 \u0627\u0644\u062a\u0646\u0638\u064a\u0645\u064a\u0629 \u0627\u0644\u0639\u0627\u0644\u0645\u064a\u0629 \u0644\u0639\u0642\u0627\u0631 MCO-010 \u0628\u062d\u0635\u0648\u0644\u0647\u0627 \u0639\u0644\u0649 \u0645\u0648\u0627\u0641\u0642\u0629 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA) \u0648\u062e\u0645\u0633\u0629 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0644\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u064a\u062a\u064a\u0645\u0629 \u0645\u0646 \u0648\u0643\u0627\u0644\u0629 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 (EMA) - \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","datePublished":"2025-09-02T11:25:37+00:00","dateModified":"2025-10-13T11:34:02+00:00","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","width":1200,"height":242},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/09\/02\/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628","description":"\u0625\u0639\u0627\u062f\u0629 \u0646\u0648\u0631 \u0627\u0644\u0623\u0645\u0644","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/9454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/comments?post=9454"}],"version-history":[{"count":8,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/9454\/revisions"}],"predecessor-version":[{"id":9816,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/9454\/revisions\/9816"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media\/8971"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media?parent=9454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/categories?post=9454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/tags?post=9454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}